Blue Jet Healthcare Limited (BLUEJET) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Blue Jet Healthcare Limited ₹115, price ₹571, upside -79.8%, quality 65 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Blue Jet Healthcare Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
35‑month range ₹320.92 – ₹1,008 · fair‑value band ₹82.38 – ₹210.63 · the ₹570.65 price screens above the ₹115.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Blue Jet Healthcare in your weekly email
Every Wednesday you see whether Blue Jet Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products.
Show more
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.
Stock analysis
Blue Jet Healthcare Limited (BLUEJET) currently trades at ₹570.65, while our model-based Fair Value estimate is ₹115.36, implying the stock looks roughly 394.6% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹390.67 per share, and 1 of the 17 models we run sit above the ₹570.65 price.
Bear case: the Dividend Discount group reads lowest at ₹12.79, and 16 of the 17 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹82.38 (bear) to ₹210.63 (bull), the price of ₹570.65 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Blue Jet Healthcare Limited reported revenue of ₹10.3B in FY2025 versus ₹4.9B in FY2021, a compound +20.2%/yr. Reported net income was ₹3.1B in FY2025, compounding +21.9%/yr from FY2021.
Key figures
Market cap ₹99.0B (≈ $1.0B) · P/E ratio 39.9 · P/S ratio 11.8 · EPS (TTM) ₹14.29 · Dividend yield 0.2% · Net margin 29.6% · Return on equity 19.9% · Return on assets (EBIT) 29.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and 74% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −80%, BLUEJET screens richer than that median.
Fair Value models
Bear ₹82.38Fair Value ₹115.36Bull ₹210.63
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (₹13.10 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+45.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.9%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+7.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.5%
Dividend (yield on the price)0.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.37% → 35%
2025 sits 86% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Compare Blue Jet Healthcare Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 648 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score65 · Top 25%
Fair Value upside−79.8% · Bottom 25%
Profitability
Return on equity (TTM)19.9% · Top 25%
Return on assets11.0% · Top 25%
Net margin (TTM)26.2% · Top 25%
Operating margin (TTM)27.6% · Top 25%
Growth and dividend
Revenue growth−31.1% · Bottom 25%
Dividend yield (TTM)0.2% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)39.9× · Pricier than median
P/B8.74× · Priciest 25%
P/S (TTM)10.45× · Pricier than median
EV/EBITDA33.3× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)80· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)4· sector 24
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Blue Jet Healthcare Limited (BLUEJET) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹115.36 versus a price of ₹570.65, about −80% upside (overvalued).
What is the fair value of BLUEJET?
Our model-based fair value for Blue Jet Healthcare Limited is ₹115.36 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹570.65.
What is the quality score of BLUEJET?
Blue Jet Healthcare Limited has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Blue Jet Healthcare Limited (BLUEJET)?
Our model-based price target is the fair value of ₹115.36 (as of Sep 27, 2026) from 17 valuation models. Cautious scenario ₹82.38, optimistic scenario ₹210.63. It is a calculation from audited fundamentals, not an analyst target.
What is the Blue Jet Healthcare Limited stock forecast for 2026?
Our models put fair value at ₹115.36, about −80% upside versus a price of ₹570.65 (overvalued). Cautious scenario ₹82.38, optimistic scenario ₹210.63. The calculation is refreshed regularly with new filings.
What is the revenue of Blue Jet Healthcare Limited (BLUEJET)?
Blue Jet Healthcare Limited reported trailing-twelve-month revenue of about ₹9.5B (latest available figure, as of Sep 27, 2026).
Does Blue Jet Healthcare Limited pay a dividend?
Blue Jet Healthcare Limited currently shows a dividend yield of about 0.21% relative to its recent price (as of Sep 27, 2026).
What is the intrinsic value of Blue Jet Healthcare Limited (BLUEJET)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Blue Jet Healthcare Limited it is ₹115.36 per share (as of Sep 27, 2026), against a price of ₹570.65. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Blue Jet Healthcare Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, BLUEJET trades above its calculated fair value: price ₹570.65, fair value ₹115.36, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BLUEJET?
No. The price is what the market pays today (₹570.65); the fair value is what the company's own numbers justify (₹115.36). For Blue Jet Healthcare Limited the two are ₹455.29 per share apart. That gap is exactly why we show both numbers side by side.
How much is Blue Jet Healthcare Limited worth?
The market values Blue Jet Healthcare Limited at about ₹99.0B (market capitalisation, as of Sep 27, 2026). Per share that is ₹570.65; our models calculate a fair value of ₹115.36 per share.
What do the bullish and bearish scenarios say about BLUEJET?
Our models span a range for Blue Jet Healthcare Limited: cautious scenario ₹82.38, base ₹115.36, optimistic ₹210.63 per share (as of Sep 27, 2026, price ₹570.65). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BLUEJET?
Blue Jet Healthcare Limited trades at a price-to-earnings ratio of 39.9 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹115.36 is built from several models across several years. Other multiples: P/B 8.7, P/S 10.5, EV/EBITDA 33.3.
How solid is the balance sheet of Blue Jet Healthcare Limited (BLUEJET)?
Balance-sheet figures for Blue Jet Healthcare Limited (as of Sep 27, 2026): return on equity 19.9%. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is BLUEJET from its 52-week high?
Blue Jet Healthcare Limited trades at ₹570.65, about 16% below its 52-week high of ₹682.35 and 74% above the low of ₹327.25 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of ₹115.36 is for.
Which stocks are comparable to Blue Jet Healthcare Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Blue Jet Healthcare Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹570.65, calculated fair value ₹115.36 (−80%), Quality Score 65/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BLUEJET calculated?
We run Blue Jet Healthcare Limited through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹115.36, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. Blue Jet Healthcare Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Blue Jet Healthcare Limited (BLUEJET)?
The closing price on Sep 25, 2026 was ₹570.65. Our model-based fair value is ₹115.36, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Blue Jet Healthcare Limited right now?
The price sits above even our optimistic bull case (₹210.63). The favourable scenario is already priced in. Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹82.38 to ₹210.63) leaves room in how you read the outcome.
Key figures of Blue Jet Healthcare Limited
How large is the market capitalisation of Blue Jet Healthcare Limited (BLUEJET)?
The market capitalisation of Blue Jet Healthcare Limited is ₹99.0B (≈ $1.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Blue Jet Healthcare Limited (BLUEJET)?
The price-to-sales ratio of Blue Jet Healthcare Limited is 11.8 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Blue Jet Healthcare Limited (BLUEJET)?
Earnings per share at Blue Jet Healthcare Limited are ₹14.29 (price ÷ EPS = P/E 39.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Blue Jet Healthcare Limited (BLUEJET)?
The dividend yield of Blue Jet Healthcare Limited is 0.2% (payout 8.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Blue Jet Healthcare Limited (BLUEJET)?
The net margin of Blue Jet Healthcare Limited is 29.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Blue Jet Healthcare Limited (BLUEJET)?
The return on equity (ROE) of Blue Jet Healthcare Limited is 19.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Blue Jet Healthcare Limited (BLUEJET)?
On an EBIT basis the return on assets of Blue Jet Healthcare Limited is 29.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Blue Jet Healthcare Limited (BLUEJET)?
The operating margin of Blue Jet Healthcare Limited is 27.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Blue Jet Healthcare Limited (BLUEJET)?
Revenue at Blue Jet Healthcare Limited is growing −31.1% versus a year earlier (3y avg +15.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Blue Jet Healthcare Limited (BLUEJET)?
Earnings per share at Blue Jet Healthcare Limited are growing −41.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Blue Jet Healthcare Limited (BLUEJET) generate?
The free cash flow of Blue Jet Healthcare Limited is −₹341M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Blue Jet Healthcare Limited (BLUEJET) hold?
Blue Jet Healthcare Limited holds more cash than debt, ₹998M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Blue Jet Healthcare Limited in the live analysis
One click puts Blue Jet Healthcare Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
